Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2019-02-15 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed by Cellid Co., Ltd. with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a public offering, including subscription and allocation status, shareholding changes, and the use of proceeds. This type of filing is a standard regulatory report regarding capital changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2019-02-15 Korean
투자설명서
Regulatory Filings Classification · 99% confidence The document is a 'Investment Prospectus' (투자설명서) for Cellid Co., Ltd. (주식회사 셀리드) dated January 29, 2019. It details the offering of 1,200,000 shares, provides information on the offering price, subscription period, and includes extensive sections on investment risks, business pipelines, and management information. This is a formal regulatory document filed for a public offering of securities, which falls under the category of a Prospectus/Proxy Solicitation/Information Statement. Given the specific options provided, 'Proxy Solicitation & Information Statement' (PSI) is the most appropriate classification for a document that serves as a formal investment prospectus for shareholders and potential investors.
2019-01-29 Korean
증권신고서(지분증권)
Regulatory Filings Classification · 99% confidence The document is a '증권신고서' (Securities Registration Statement) filed by Cellid Co., Ltd. with the Financial Services Commission (FSC) in South Korea. It contains detailed information regarding the company's business, financial risks, pipeline development, and the terms of a public offering of shares. This document is a formal regulatory filing required for companies planning to issue securities to the public, which falls under the category of a Securities Registration Statement. In the provided taxonomy, this is best classified as a Regulatory Filing (RNS) as it is a formal legal/regulatory document that does not fit into the specific categories like 10-K (Annual Report) or IP (Investor Presentation).
2019-01-07 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.